CN1687033A - Medication for anti virus of respiratory tract and application - Google Patents
Medication for anti virus of respiratory tract and application Download PDFInfo
- Publication number
- CN1687033A CN1687033A CN 200510018613 CN200510018613A CN1687033A CN 1687033 A CN1687033 A CN 1687033A CN 200510018613 CN200510018613 CN 200510018613 CN 200510018613 A CN200510018613 A CN 200510018613A CN 1687033 A CN1687033 A CN 1687033A
- Authority
- CN
- China
- Prior art keywords
- medicine
- virus
- group
- cell
- arbidol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The present invention discloses a medicine with obvious antiviral effect for resisting coxsackie virus, adenovirus Ad7, parafinflueza virus and rhinovirus. Said invention also provides the general formula of said medicine.
Description
Technical field
The present invention relates to a kind of new antiviral drug arbidol HCl, and the effect of the anti-various respiratory road virus of this medicine.Specifically, the invention belongs to a kind of new compound with good resistance virus activity, this compound is preparing the application that can bring into play in anti-Coxsackie B virus 3, adenovirus Ad7, parainfluenza virus, the rhinovirus medicine.
Background technology
Influenza and acute respiratory virus infection are sickness rate height, disease that the morbidity scope is wide clinically, and because of influenza virus has antigenic variability, it has multi-drug resistant in addition, needs a kind of medicine for the treatment of safely and effectively and preventing badly.Chemicals occupies very consequence on treatment influenza and ARVI.Up to now, amantadine and amantadine derivative Rimantadine as antiviral in wide clinical application, but its field of activity narrower (only effective) to A type influenza virus, and have side effect, and along with its resistance of clinical application also increases simultaneously.Arbidol HCl is the non-nucleoside antiviral, be that at first develop in USSR (Union of Soviet Socialist Republics) pharmaceutical chemistry research centre, 1993 in Russian Initial Public Offering, be a new antiviral and an immunostimulant, be used to prevent and treat influenza and the sense of other acute respiratory virus, it is the most remarkable to the antiviral activity of first, Influenza B virus, this medicine can suppress the commitment that first, Influenza B virus duplicates, and can suppress the fusion of virus and cell serous coat and the film between virus and the interior endocytic vesicle and merge (PH=5.0).Simultaneously arbidol HCl also can be induced the generation Interferon, rabbit in vivo, and the phagocytic function of scavenger cell is had significant activation, has immunoregulation effect.And this medicine yet there are no report and discovery in anti-Coxsackie B virus 3, adenovirus Ad7, parainfluenza virus, rhinoviral effect.
Summary of the invention
The object of the present invention is to provide a kind of compound-arbidol HCl with pharmaceutical use, this compound is to influenza virus A type and B-mode curative effect and prevent obviously easy administration, well-tolerated.
Another object of the present invention is to provide the application of a kind of arbidol HCl in the anti-Coxsackie virus of preparation, adenovirus Ad7, parainfluenza virus, rhinovirus medicine.
A kind of new antiviral drug--arbidol HCl (Arbidol Hydrochloride), chemistry 6-bromo-4-(dimethyl aminomethyl) by name-5-hydroxyl-1-methyl-2-(benzene thiomethyl)-1H-indoles-3-hydroxy acid carbethoxy hydrochloride-hydrate, be the crystalline powder of white, molecular weight 531.89 does not contain the bioactive added compound of influence and other impurity.Its chemical structural formula is as follows:
Wherein HO-represents hydroxyl, and Br-represents bromine, CH
3-expression methyl, CH
2N (CH
3)
2-expression dimethyl aminomethyl, COOC
2H
5-hydroxy acid base, HCL represents hydrochloric acid ,-CH
2S-represents thiomethyl, H
2O represents water.
Arbidol HCl has anti-Coxsackie B virus 3, adenovirus Ad7, parainfluenza virus, rhinoviral pharmacodynamic action, and tangible antivirus action is arranged in antiviral biosynthesizing.
2 and 3 to be starting raw material, make target compound 1 through addition, cyclization, bromination, acidylate, replacement and Mannich reaction.Overall yield of reaction 26.6%.The synthetic technology route is as follows:
Arbidol HCl is a water soluble drug, but solubleness is general, and DMSO (dimethyl sulfoxide (DMSO)) can promote its dissolving.Whether contain the toxicity of factor affecting arbidol HCls such as chaotropic agent DMSO, medicated disinfecting mode and drug effect cell time to HEp-2 cell (people's laryngocarcinoma cell) and hel cell (human embryonic lung cell).Medicine pair cell toxic action shows as refractivity to be increased, and wall thickness becomes circle, and fragmentation comes off, and light absorption value descends.Along with the increase of drug level, cell survival rate reduces the toxic action of medicine pair cell within the specific limits.
Arbidol hydrochloride is external to have anti-Coxsackie virus effect, the anti-Coxsackie virus biosynthesizing of arbidol HCl group can obviously alleviate CVB3 cells infected CPE degree, along with the increase of drug dose, cell shrinkage, become and the CPE feature such as to justify, come off, be cracked and weaken gradually.Arbidol HCl can reduce virus titer in the supernatant, and viral inhibiting rate and drug level are proportionate, and virus titer then is negative correlation with drug level.The direct deactivation group of the antiviral absorption of the antiviral biosynthesizing group＞medicine of the anti-CVB3 index of arbidol HCl (TI) medicine 8h group＞medicine.
Arbidol HCl has the biosynthetic effect of obvious inhibition adenovirus Ad7, shows: along with the increase of drug level, cellular swelling becomes circle, and typical CPE such as diopter enhancing weaken gradually, and viral inhibiting rate obviously raises.In the scope of certain drug level,,, and show dose-effect relationship to the inhibiting rate increase of Ad7 along with the increase of drug level.Arbidol HCl is invaded adenovirus does not have blocking-up (prevention) effect, does not also have direct killing effect.
Arbidol HCl has external anti-parainfluenza virus toxic action, obviously viral interference biosynthesizing, and along with the increase of drug level, typical CPE such as cellular swelling, change circle, synplasm formation weaken gradually, and viral inhibiting rate obviously raises.And in the finite concentration scope,,, and show dose-effect relationship to the inhibiting rate increase of RSV along with the increase of drug level.The absorption that arbidol HCl can stop RSV virus with penetrate cell, and act on the 6h curative effect in advance and obviously be better than and act on 2h in advance.Arbidol HCl does not have direct killing effect to parainfluenza virus.
Arbidol HCl has the obvious suppression effect to the propagation of rhinovirus in hel cell, increase along with drug level, cell shrinkage, become justify, come off, CPE feature such as refractivity enhancing weakens gradually, the virus inhibiting rate raises, the medicine antiviral activity strengthens, and is proportionate between drug level and the viral inhibiting rate.
The application of arbidol HCl in acute respiratory virus infection medicines such as the anti-Coxsackie virus of preparation, adenovirus Ad7, parainfluenza virus, rhinovirus.
Arbidol HCl can be made into thin membrane coated tablet, capsule, granule, dispersion agent, and is oral.When preparing above-mentioned preparation, can use conventional preparation technique.In the medicine of treatment acute respiratory virus infection and complication thereof, can add this medicine composition or in therapeutic process drug combination use this medicine.Foreign study report, arbidol HCl carries out clinical study during the flu outbreak of 1983 to nineteen ninety as antiviral, comprises that altogether 9500 are the patient.For grownup's Arbidol coating tablet as treatment and prevention by A, influenza that Type B virus causes and the drug administration 0.1g of other acute respiratory virus infection.The treatment influenza, Arbidol is advised oral 0.2g, taking medicine before meal usefulness, every day 4 times, for three days on end.For the people who contacts with the urgent patient, flu-prevention oral 0.2g suggestion ante cibum, every day 1 time, continuous 5～10 days.For the prevention of the acute respiratory disease that is in influenza period, Arbidol oral 0.1g suggestion ante cibum, 2 times weekly, continuous 20 days.The resistance that Arbidol is done well in the clinical study that has more than 9000 patient to participate in; The no side effects report.
The present invention compared with prior art has the following advantages and effect: 1. pair influenza virus A type and B-mode all effective.2. existing therapeutic action also has prophylactic effect; 3. have the direct dual function that suppresses virus and induce endogenous interferon concurrently.4. Orally-administrable is easy to use.5. be non-nucleosides compound, low, the well-tolerated of toxicity.
Embodiment
Embodiment 1: arbidol HCl is to the cytotoxicity of HEp-2 cell and hel cell
With trypsinase well-grown HEp-2 cell and hel cell are dispersed into the individual cells suspension, by 1 * 10
5/ ml concentration branch is planted in 96 orifice plates, and every hole 0.1ml puts 37 ℃, 5%CO
2Cultivate 24h in the incubator.After treating that cell grows up to individual layer, abandon the nutrient solution supernatant, change the pastille that contains different concns and keep liquid, each concentration is established four multiple holes, and establishes the normal cell contrast.Continue to cultivate 48h, abandon culture supernatant, every hole adds the MEM substratum that does not the contain serum 50 μ l that contain 5mg/mlMTT (tetramethyl-azo azoles salt), puts CO
2After continuing in the incubator to cultivate 2～3h, abandon the MTT supernatant, PBS washes 3 times, every hole adds lysate (DMSO: the ethanol volume ratio is 1: 1) 100 μ l, vibrated 5～10 minutes, the place reads the OD value at microplate reader 570nm wavelength, and calculates cell survival rate according to following formula, finds out the median toxic concentration (TD50) and the maximal non-toxic concentration (TD of medicine pair cell
0).
Cell survival rate (%)=(experimental port OD value/control group OD value) * 100%
Medicine all shows as to refractivity increases the toxic action of two kinds of cells, and wall thickness becomes circle, and fragmentation comes off, and light absorption value descends.Along with the increase of drug level, cell survival rate reduces the toxic action of medicine pair cell, the results are shown in following table within the specific limits
Arbidol HCl is to the toxic action of HEp-2 cell and hel cell under the different sterilization methods of table 1
| The experiment group | Cell survival rate (%) during different pharmaceutical concentration (μ g/mL) | ??TC 50 | ||||||||||
| ??10 | ??20 | ??40 | ??80 | ??100 | ??160 | ??250 | ??320 | ??500 | ??640 | ??1000 | ||
| 1 group 2 groups 3 groups 4 groups | ??117 ??102.4 ??99.05 ??89 | ??69 ??92.80 ??84.32 ??73 | ??70 ??80.60 ??60.80 ??80 | ??63 ??- ??44.18 ??67 | ??- ??81.07 ??- ??- | ??26 ??- ??41.80 ??39 | ??- ??70.4 ??- ??- | ??32 ??- ??- ??40 | ??- ??69.33 ??- ??- | ??28 ??- ??- ??43 | ??- ??51.2 ??- ??- | ??199.2 ??986.54 ??85.39 ??464.5 |
-expression individual concentrations is not done
1 group of arbidol HCl is made aqua with dimethyl sulfoxide (DMSO) (DMSO) and distilled water (V: V is 1: 1), after the filtration sterilization to the toxicity of HEp-2 cell.
2 groups of arbidol HCls are with dimethyl sulfoxide (DMSO) (DMSO) and distilled water (V: V is 1: 9) dissolving, after the filtration sterilization to the toxicity of HEp-2 cell.
3 groups of arbidol HCls are with dimethyl sulfoxide (DMSO) (DMSO) and distilled water (V: V is 1: 9) dissolving, behind 8 pounds of 15min high pressure to the toxicity of HEp-2 cell.
4 groups of arbidol HCls are made aqua with ddH2O, after the filtration sterilization to the toxicity of hel cell.
Embodiment 2: the external anti-Coxsackie virus effect of arbidol HCl
Draft arbidol HCl the effect of CVB3 is divided into four groups.I organizes (the antiviral biosynthesizing group of medicine): add earlier and add pastille again behind the viral liquid adherent cell 2h and keep liquid.II organizes (directly effect group of medicine): the drug effect 2h of viral liquid and different concns, change cell maintenance medium after then mixed solution and cell being hatched 2h.III group and IV group (the antiviral absorption of medicine 2h, 8h group): with the medicine of different concns join act on 2h, 8h respectively in the cell after, discard soup, add viral liquid again, change cell maintenance medium after adsorbing 2h.
The above-mentioned four groups of every hole of experimental group dosage are established 4 repeating holes, set up non-infected cells contrast, virus control and solvent control simultaneously.35 ℃, 5%CO2 cultivation, every day, observation of cell changed under inverted microscope.Treat virus control porocyte pathology (Cytopathic effect, CPE) degree is ++ +～++ ++, and control cells is just often, mtt assay carries out viable cell dyeing, read the OD value at the 570nm wavelength, judge the size of different concns medicine to viral inhibition according to the OD value, formula is as follows:
Get the culture supernatant series log10 dilution of experimental port, virus control hole, cell control well, measure the TCID50Probit homing method and calculate medicine median toxic concentration (TD50) and medium effective concentration (ED50), therapeutic index (TI)=medicine median toxic concentration (TD50)/medium effective concentration (ED50), calculate the TCID50 of virus with the Reed-Muench method, use the LSD method and carry out comparing in twos between the different groups, judge that difference has or not significance therebetween, data processing is finished with SPSS 11.5 softwares.
Experiment shows that the antiviral biosynthesizing group of arbidol hydrochloride can obviously alleviate CVB3 cells infected CPE degree, along with the increase of drug dose, cell shrinkage, becomes and the CPE feature such as justifies, comes off, be cracked and weaken gradually in the antiviral biosynthesizing group of Arbidol.Arbidol can reduce virus titer in the supernatant, and viral inhibiting rate and drug level are proportionate, and virus titer then is negative correlation with drug level.The DMSO control group shows that DMSO does not have antivirus action.The direct deactivation group of the antiviral absorption of the antiviral biosynthesizing group＞medicine of the anti-CVB3 index of arbidol HCl (TI) medicine 8h group＞medicine illustrates that this medicine mainly is by suppressing the synthetic antivirus action of bringing into play of viral organism.
The virus inhibiting rate relatively during the anti-CVB3 difference of the table 2 arbidol HCl mode of action
| The experiment group | Drug level (μ g/mL) | ???????ED 50?????(μg/mL) | ????TI | ||||||
| ??5 | ?10 | ?20 | ??40 | ??80 | ??160 | ||||
| The I group | ??① | ??0 | ?44.63 | ?46.83 | ??73.28 | ??75.48 | ??66.67 | ??46.48(p＜0.01) | ??19.29 |
| ??② | ??10 -11.3 | ?10 -6.3 | ?10 -5.8 | ??10 -2.3 | ??10 -2.3 | ??10 -4.3 | |||
| The II group | ??① | ??0 | ?12.35 | ?35.80 | ??41.98 | ??45.68 | ??45.68 | ??138.59(p＜ ??0.01) | ??6.47 |
| ??② | ??10 -11.3 | ?10 -11.3 | ?10 -8.8 | ??10 -6.3 | ??10 -6.3 | ??10 -6.3 | |||
| The III group | ??① | ??17.89 | ?20.64 | ?27.98 | ??27.06 | ??28.90 | ??27.06 | ??578.44(p＞ ??0.05) | ??1.55 |
| ??② | ??10 -11.3 | ?10 -11.3 | ?10 -11.3 | ??10 -11.3 | ??10 -11.3 | ??10 -11.3 | |||
| The IV group | ??① | ??20.53 | ?24.80 | ?40.80 | ??47.73 | ??48.27 | ??44.53 | ??134.10(p＜ ??0.01) | ??6.69 |
| ??② | ??10 -11.3 | ?10 -11.3 | ?10 -5.8 | ??10 -6.3 | ??10 -5.8 | ??10 -6.3 | |||
I group: the antiviral biosynthesizing group of medicine; II group: directly effect group of medicine; III group: the antiviral absorption of medicine 2h group; IV group: the antiviral absorption of medicine 8h group; 1.: viral inhibiting rate; 2.: the viral supernatant titre
Embodiment 3: the external anti-adenovirus Ad7 effect of arbidol HCl
Draft arbidol HCl the effect of adenovirus Ad7 is divided into four groups.I organizes (the antiviral biosynthesizing group of medicine): add earlier and add pastille again behind the viral liquid adherent cell 2h and keep liquid.II organizes (directly effect group of medicine): the drug effect 2h of viral liquid and different concns, change cell maintenance medium after then mixed solution and cell being hatched 2h.III group, IV group and V group (the antiviral absorption of medicine 2h, 4h, 8h group): with the medicine of different concns join act on 2h, 4h, 8h respectively in the cell after, discard soup, add viral liquid again, change cell maintenance medium behind the absorption 2h.
The above-mentioned five groups of every hole of experimental group dosage are established 4 repeating holes, set up non-infected cells contrast, virus control and solvent control simultaneously.35 ℃, 5%CO2 cultivation, every day, observation of cell changed under inverted microscope.Treat virus control porocyte pathology (Cytopathic effect, CPE) degree is ++ +～++ ++, and control cells is just often, mtt assay carries out viable cell dyeing, read the OD value at the 570nm wavelength, judge the size of different concns medicine to viral inhibition according to the OD value, formula is as follows:
The Probit homing method calculates medicine median toxic concentration (TD50) and medium effective concentration (ED50), therapeutic index (TI)=medicine median toxic concentration (TD50)/medium effective concentration (ED50), with LinearRegression the cytological effect (cell survival rate, inhibiting rate) of drug dose and its generation is carried out correlation analysis, judge whether the amount effect relationship.
Experimental result shows that arbidol HCl has the biosynthetic effect of obvious inhibition adenovirus Ad7, shows: along with the increase of drug level, cellular swelling becomes circle, and typical CPE such as diopter enhancing weaken gradually, and viral inhibiting rate obviously raises.In the scope of certain drug level,,, and show dose-effect relationship to the inhibiting rate increase of Ad7 along with the increase of drug level.Arbidol HCl is invaded adenovirus does not have blocking-up (prevention) effect, does not also have direct killing effect.The results are shown in following table:
Table 3 arbidol HCl is to the biosynthetic restraining effect of Ad7
| Drug dose (μ g/mL) | Cytopathic effect | Virus inhibiting rate % | ?ED 50(μg/mL) | ????TI |
| 5 10 15 20 25 30 cells contrast virus control | ??+++ ??+++ ??++ ??++ ? ??+ ??- ??- ??++++ | ??26.10 ??37.61 ??50.37 ??60.15 ? ??65.53 ??87.58 ??100 ??0 | ? ? ? ? ??15.39 ? ? ? ? | ? ? ? ? ??4.26 ? ? ? ? |
++ ++: 75% above cytopathy; +++: 75%～50% cytopathy; ++: 50%～25% cytopathy; +: 25% following cytopathy;-: acellular pathology
Embodiment 4: the external anti-parainfluenza virus toxic action of arbidol HCl
Draft arbidol HCl the effect of parainfluenza virus is divided into four groups.I group (the synthetic group of the anti-low titre viral organism of medicine): add viral liquid 10 earlier
-2Add pastille behind the adherent cell 2h again and keep liquid.II organizes (the anti-infectious titer biosynthesizing of medicine group): add viral liquid 10 earlier
-3Add pastille behind the adherent cell 2h again and keep liquid.III group and IV group (the antiviral absorption of medicine 2h, 6h group): with the medicine of different concns join act on 2h, 6h respectively in the cell after, discard soup, add viral liquid again, change cell maintenance medium after adsorbing 2h.
The above-mentioned four groups of every hole of experimental group dosage are established 4 repeating holes, set up non-infected cells contrast, virus control and solvent control simultaneously.35 ℃, 5%CO2 cultivation, every day, observation of cell changed under inverted microscope.Treat virus control porocyte pathology (Cytopathic effect, CPE) degree is ++ +～++ ++, and control cells is just often, mtt assay carries out viable cell dyeing, read the OD value at the 570nm wavelength, judge the size of different concns medicine to viral inhibition according to the OD value, formula is as follows:
The Probit homing method calculates medicine median toxic concentration (TD50) and medium effective concentration (ED50), therapeutic index (TI)=medicine median toxic concentration (TD50)/medium effective concentration (ED50), with LinearRegression the cytological effect (cell survival rate, inhibiting rate) of drug dose and its generation is carried out correlation analysis, judge whether the amount effect relationship.
Experimental result shows that arbidol HCl has external anti-parainfluenza virus toxic action, obviously viral interference biosynthesizing, and along with the increase of drug level, typical CPE such as cellular swelling, change circle, synplasm formation weaken gradually, and viral inhibiting rate obviously raises.And in the finite concentration scope,,, and show dose-effect relationship to the inhibiting rate increase of RSV along with the increase of drug level.The absorption that arbidol HCl can stop RSV virus with penetrate cell, and act on the 6h curative effect in advance and obviously be better than and act on 2h in advance.Arbidol HCl does not have direct killing effect to parainfluenza virus.The results are shown in following table:
The virus inhibiting rate relatively during the anti-parainfluenza virus difference of the table 4 arbidol HCl mode of action
| The experiment group | Drug level (μ g/mL) | ????ED 50??(μg/mL) | ?????TI | ||||||||
| ??2 | ??4 | ??6 | ??8 | ??10 | ??12.5 | ??15 | ??20 | ??25 | |||
| I group II group III group IV group | ??40.23 ??- ??- ??27.76 | ??58.62 ??0 ??- ??34.63 | ??66.67 ??10.67 ??- ??46.30 | ??70.11 ??18.97 ??0 ??- | ??- ??20.55 ??- ??52.14 | ??- ??28.59 ??2.68 ??78.60 | ??81.60 ??50.19 ??5.60 ??- | ??- ??50.59 ??36.98 ??77.56 | ??- ??- ??40.39 ??- | ??2.46 ??17.64 ??25.18 ??8.00 | ??34.71 ??4.84 ??3.39 ??10.67 |
I group: the synthetic group of the anti-low titre viral organism of medicine; II group: the anti-infectious titer biosynthesizing of medicine group; III group: the anti-low titre virus absorption 4h group of medicine; The anti-low titre virus absorption 6h group of IV group medicine
Embodiment 5: arbidol HCl is external to the effect of rhinovirus inhibition of proliferation
Use 100TCID earlier
50The every hole of the rhinovirus of/0.1ml 0.1ml cells infected behind the absorption 2h, is inhaled virus removal, adds the medicine of different concns, and every hole dosage is established 4 repeating holes, sets up non-infected cells contrast, virus control and solvent control simultaneously.35 ℃, 5%CO2 cultivation, every day, observation of cell changed under inverted microscope.Treat virus control porocyte pathology (Cytopathic effect, CPE) degree is ++ +～++ ++, and control cells is just often, mtt assay carries out viable cell dyeing, read the OD value at the 570nm wavelength, judge the size of different concns medicine to viral inhibition according to the OD value, formula is as follows:
The Probit homing method calculates medicine median toxic concentration (TD50) and medium effective concentration (ED50), therapeutic index (TI)=medicine median toxic concentration (TD50)/medium effective concentration (ED50), with LinearRegression the cytological effect (cell survival rate, inhibiting rate) of drug dose and its generation is carried out correlation analysis, judge whether the amount effect relationship.
Arbidol HCl has the obvious suppression effect to the propagation of rhinovirus in hel cell, increase along with drug level, cell shrinkage, become justify, come off, CPE feature such as refractivity enhancing weakens gradually, the virus inhibiting rate raises, the medicine antiviral activity strengthens, and is proportionate between drug level and the viral inhibiting rate.The results are shown in following table:
The effect of table 5 arbidol HCl rhinovirus
| Drug level (μ g/mL) | ????ED50 ??(μg/mL) | |||||
| ??8 | ??16 | ??32 | ??64 | ??128 | ||
| Virus inhibiting rate (%) | ??14 | ??19 | ??57 | ??58 | ??157 | ????44.4 |
Claims (5)
1, the compound of following general formula (I) expression arbidol HCl:
Wherein HO-represents hydroxyl
Br-represents bromine
CH
3-expression methyl
CH
2N (CH
3)
2-expression dimethyl aminomethyl
-COOC
2H
5-hydroxy acid ethyl ester
-CH
2S-represents thiomethyl
HCL represents hydrochloric acid
H
2O represents water
2, the application of the arbidol HCl in the claim 1 in the anti-Coxsackie virus medicine of preparation.
3, the application of the arbidol HCl in the claim 1 in the anti-adenovirus Ad7 medicine of preparation
4, the application of the arbidol HCl in the claim 1 in the anti-parainfluenza virus cytotoxic drug of preparation.
5, the application of the arbidol HCl in the claim 1 in preparation rhinovirus medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100186139A CN100364975C (en) | 2005-04-26 | 2005-04-26 | Medication for anti virus of respiratory tract and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100186139A CN100364975C (en) | 2005-04-26 | 2005-04-26 | Medication for anti virus of respiratory tract and application |
Related Child Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200710137481 Division CN101073569A (en) | 2005-04-26 | 2005-04-26 | Medicine for preventing respiratory viruses and its use |
| CN 200710137483 Division CN101084893A (en) | 2005-04-26 | 2005-04-26 | Anti-respiratory virus medicine and use |
| CNB2007101374825A Division CN100569237C (en) | 2005-04-26 | 2005-04-26 | A kind of medicine of anti-adenovirus and purposes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1687033A true CN1687033A (en) | 2005-10-26 |
| CN100364975C CN100364975C (en) | 2008-01-30 |
Family
ID=35305075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100186139A Expired - Fee Related CN100364975C (en) | 2005-04-26 | 2005-04-26 | Medication for anti virus of respiratory tract and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100364975C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102786461A (en) * | 2011-05-18 | 2012-11-21 | 中国医学科学院药物研究所 | Arbidol hydrochloride crystal E, its preparation method and its applications in medicines and healthcare products |
| CN102786463A (en) * | 2012-07-02 | 2012-11-21 | 浙江金伯士药业有限公司 | Method for preparing 5-acetoxyl-3-indole carboxylic acid ethyl ester |
| CN102786462A (en) * | 2011-05-18 | 2012-11-21 | 中国医学科学院药物研究所 | Arbidol hydrochloride crystal B, its preparation method, and its applications in medicines and healthcare products |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1685933A1 (en) * | 1974-11-27 | 1991-10-23 | Всесоюзный Научно-Исследовательский Химико-Фармацевтический Институт Им.С.Орджоникидзе | Chlorohydrate of 1-methyl-2-phenylthiomethyl-3-carboethoxy-4 -dimethylaminomethyl-5-oxy-6-bromoindole having antivirus action and method for obtaining it |
| RU2008004C1 (en) * | 1986-06-25 | 1994-02-28 | Центр по химии лекарственных средств - ВНИХФИ | Prophylactic and curative agent for treating flu virus b |
| RU2033157C1 (en) * | 1987-12-16 | 1995-04-20 | Центр по химии лекарственных средств | Drug possessing interferon-inducing and immunomodulating (immunostimulating) activity |
| DE3891468T1 (en) * | 1989-01-12 | 1991-02-21 | Vni Skij Chimiko Farmacevtices | AETHYL ESTER OF 6-BROM-5-HYDROXY-4-DIMETHYLAMINOMETHYL-1-METHYL-2-PHENYLTHIOMETHYLINDOL-3-CARBONIC ACID OF MONOHYDRATE HYDROGEN CHLORIDE, METHOD FOR ITS PRODUCTION OF INTERMEDIATE CLEANING |
-
2005
- 2005-04-26 CN CNB2005100186139A patent/CN100364975C/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102786461A (en) * | 2011-05-18 | 2012-11-21 | 中国医学科学院药物研究所 | Arbidol hydrochloride crystal E, its preparation method and its applications in medicines and healthcare products |
| CN102786462A (en) * | 2011-05-18 | 2012-11-21 | 中国医学科学院药物研究所 | Arbidol hydrochloride crystal B, its preparation method, and its applications in medicines and healthcare products |
| CN102786461B (en) * | 2011-05-18 | 2016-08-31 | 中国医学科学院药物研究所 | Arbidol hydrochloride crystalline substance E type and preparation method are applied with in medicine and health product |
| CN102786462B (en) * | 2011-05-18 | 2016-08-31 | 中国医学科学院药物研究所 | Arbidol hydrochloride crystal B-type and preparation method are applied with in medicine and health product |
| CN102786463A (en) * | 2012-07-02 | 2012-11-21 | 浙江金伯士药业有限公司 | Method for preparing 5-acetoxyl-3-indole carboxylic acid ethyl ester |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100364975C (en) | 2008-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU642023B2 (en) | Anti-virus agent | |
| CN1316968C (en) | Application of indole-2,3-diketone in preparing medication for antivirus or immunopotenfiator | |
| WO2023103614A1 (en) | Broad-spectrum antiviral drug, pharmaceutical composition and use thereof | |
| CN111514299A (en) | Composition for preventing and treating pneumonia and application of composition in preparation of medicine for preventing and treating pneumonia | |
| CN1687033A (en) | Medication for anti virus of respiratory tract and application | |
| CN1629160A (en) | Preparation of 13-hexyl berberine salt and its anti-virus and antibacterial action | |
| CN100569237C (en) | A kind of medicine of anti-adenovirus and purposes | |
| CN101073569A (en) | Medicine for preventing respiratory viruses and its use | |
| CN1686165A (en) | Medical nano-carbon tube composition, preparation method and its application | |
| CN1947796A (en) | Chemical modified adefovir and tynofovir | |
| CN1215334A (en) | Preventive and remedy for viral infections | |
| WO2021228009A1 (en) | Piperacillin magnesium compound, composition, preparation method and use | |
| KR20210158277A (en) | Novel benzimidazole-carbohydrate conjugate compounds with anti-cancer activity and antiviral activity and their manufacturing method | |
| CN1158566A (en) | Pharmaceutical compsn. for the prevention and/or treatment of viral infections and optionally inflammations as well as a method for treatment thereof | |
| CN1566118A (en) | Antiviral activity possessed compound and preparation method thereof | |
| CN1202861C (en) | Use of compound interferon in the treating of SARS disease | |
| CN1504196A (en) | Use of glycyrrhizin and its derivatives as mcp-1 production inhibitors | |
| CN101084893A (en) | Anti-respiratory virus medicine and use | |
| CN1468601A (en) | Picroside-II as one new medicine for preventing and treating allergic and inflammatory diseases | |
| CN111803650B (en) | Application of tyramine-fucosan in preventing virus from spreading through mucous membrane, preparation method and medicament thereof | |
| CN104174013B (en) | Composition containing hepatocyte growth-promoting factors and application thereof | |
| CN1244332C (en) | Sarcandra extract and its application | |
| CN1817868A (en) | Group of ornidazole deriative for preventing anaerobe infection and production thereof | |
| CN1903203A (en) | Application of derivative of polysubstituted acyl thiourea pyrimidine for preparing antiviral medicine | |
| JP2006514070A (en) | Bicyclic carbohydrate compounds useful for the treatment of infections caused by species belonging to the Flaviviridae family such as hepatitis C and bovine viral diarrhea viruses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080130 |